Oromax2% w/w

Oromax is an imidazole antifungal used to treat a range of superficial fungal infections. Indications vary by dosage form.

Established (approved) uses

• Vulvovaginal candidiasis (vaginal yeast infection) — vaginal cream/suppository formulations of Oromax are approved to treat vaginal yeast infections and relieve associated external itching and irritation.
• Cutaneous fungal infections — topical (skin) formulations of Oromax are approved for tinea pedis (athlete's foot), tinea cruris (jock itch), tinea corporis (ringworm), and tinea versicolor, as well as cutaneous candidiasis (including diaper dermatitis with candidal infection).
• Oropharyngeal candidiasis (oral thrush) — oral gel formulations of Oromax are used for local treatment of thrush of the mouth and throat in infants, children, and adults.

Adjunct / combination use

• In some products, Oromax is combined with a topical corticosteroid (e.g. hydrocortisone) for fungal skin infections with significant inflammation, or with an antibacterial agent (e.g. metronidazole, as a vaginal combination product) for mixed vaginal infections. These combination uses require the specific combination product, not Oromax alone.

Your physician will confirm the diagnosis and select the appropriate formulation and duration for your specific infection.

Each formulation contains Miconazole Nitrate as the active pharmaceutical ingredient, most commonly at a strength of 2% w/w, in a base appropriate to the route of administration (cream, vaginal cream/suppository/pessary, oral gel, or powder). Inactive ingredients (bases, preservatives, thickening agents) vary by manufacturer and formulation — refer to the specific product label for the complete excipient list.

Oromax is a synthetic imidazole-derivative antifungal agent. It is the nitrate salt of miconazole and is formulated for topical, vaginal, and oral (local, non-systemic) use rather than systemic administration. It is active against a broad range of dermatophytes and yeasts, most notably Candida species, and also has activity against some gram-positive bacteria.

Oromax is available in Bangladesh and internationally as topical creams, vaginal creams/pessaries, and oral gel, marketed under various local brand names.

Oromax belongs to the imidazole class of antifungal agents, used topically, vaginally, or orally (locally) for the treatment of dermatophyte and candidal infections.

Mechanism of action

Miconazole Nitrate inhibits the fungal cytochrome P450-dependent enzyme 14-alpha-demethylase, which is required to convert lanosterol to ergosterol, the principal sterol of the fungal cell membrane. Depletion of ergosterol and accumulation of toxic sterol intermediates disrupt the structure and function of the fungal cell membrane, leading to increased membrane permeability, leakage of cellular contents, and fungal cell death (fungicidal at higher concentrations, fungistatic at lower concentrations).

Spectrum of activity

Miconazole Nitrate is active against dermatophytes (Trichophyton, Microsporum, Epidermophyton species), yeasts (particularly Candida albicans and other Candida species), and Malassezia furfur (the organism responsible for tinea versicolor). It also has some activity against certain gram-positive bacteria.

Pharmacokinetics

Topical, vaginal, and oral-gel forms of Miconazole Nitrate are designed for local action with minimal systemic absorption. However, some systemic absorption does occur — particularly with vaginal and oral mucosal use — and this small absorbed fraction is sufficient to inhibit hepatic CYP3A4 and CYP2C9 enzymes, which is the basis for clinically significant drug interactions (see Drug Interactions).

Topical cream: Clean and dry the affected area, then apply a thin layer and gently rub in.

Vaginal cream/suppository: Insert using the applicator provided, preferably at bedtime while lying down, as far into the vagina as comfortably possible.

Oral gel: Apply small amounts to the affected areas of the mouth using a clean finger, after meals; allow the gel to remain in contact with the oral mucosa as long as possible before swallowing. For infants, apply in small amounts across the inside of the cheeks to avoid the risk of choking, and avoid contact with the back of the throat.

Do not use Oromax in the eyes. Complete the full prescribed course even if symptoms improve early, to reduce the risk of recurrence.

Although Oromax is applied topically, vaginally, or orally for local effect, a small amount can be absorbed systemically and is sufficient to inhibit the hepatic enzymes CYP3A4 and CYP2C9, producing clinically significant interactions:

• Warfarin and other oral anticoagulants: Oromax can significantly potentiate anticoagulant effect, increasing the risk of bleeding or bruising — this interaction has been reported even with topical and vaginal use. Patients on warfarin should have their INR monitored closely if Oromax is used, and should report any unusual bleeding or bruising promptly.
• Phenytoin: concurrent use may increase phenytoin levels, risking toxicity; phenytoin levels should be monitored.
• Cyclosporine and tacrolimus: Oromax may increase blood levels of these immunosuppressants, risking nephrotoxicity; monitoring is advised with significant systemic exposure (e.g. extensive oral or vaginal use).
• Terfenadine, astemizole, cisapride (largely historical/withdrawn agents): concurrent use with Oromax is contraindicated due to the risk of serious cardiac arrhythmias from elevated levels of these agents.
• Latex products: vaginal formulations of Oromax may weaken latex condoms and diaphragms, reducing their effectiveness in preventing pregnancy and sexually transmitted infections, for several days after use.

Inform your physician or pharmacist about all medicines you are taking, especially oral anticoagulants, before using Oromax.

Side effects of Oromax depend on the route of administration and are generally mild and local.

Common

• Local burning, stinging, itching, or irritation at the application site (skin, vaginal, or oral mucosa)
• Vaginal formulations: increased vaginal discharge, mild pelvic or abdominal cramping
• Oral gel: unpleasant taste, mild nausea

Less common

• Nausea, vomiting, or diarrhea (more often with prolonged oral gel use)
• Skin rash, contact dermatitis

Rare but serious

• Allergic reactions, including hives, swelling of the face/lips/tongue, and, rarely, severe allergic reactions requiring immediate medical attention

Stop use and consult a physician if severe irritation, rash, or signs of an allergic reaction occur.

Pregnancy: Data on Oromax in human pregnancy are limited, particularly for oral and extensive vaginal/topical use. Oromax should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; vaginal applicators may not be recommended in the first trimester without medical guidance, as insertion technique may need to be adapted. Always consult a physician before use during pregnancy.

Lactation: It is not well established whether topically or vaginally applied Oromax is excreted in human breast milk in clinically significant amounts. As a precaution, breastfeeding mothers should consult a physician before use, and avoid applying Oromax directly to the breast/nipple area if breastfeeding.

• For external, vaginal, or oral mucosal use only — avoid contact with the eyes; if accidental eye contact occurs, rinse thoroughly with water.
• If this is the first time you have experienced symptoms of a suspected vaginal yeast infection, consult a physician for diagnosis before self-treating with Oromax, as similar symptoms can be caused by other conditions.
• Seek medical advice if vaginal/abdominal symptoms are accompanied by fever, foul-smelling discharge, or lower abdominal/back/shoulder pain, as these may indicate a more serious condition.
• Patients on warfarin or other oral anticoagulants require close monitoring — see Drug Interactions.
• Vaginal formulations of Oromax may damage latex condoms and diaphragms.
• Discontinue and consult a physician if irritation, sensitization, or an allergic reaction develops.
• Use the full prescribed duration even if symptoms resolve early, to reduce recurrence risk.
• Patients with recurrent or persistent infections despite treatment with Oromax should be evaluated for underlying conditions such as diabetes mellitus or immunosuppression (including HIV).

Significant systemic toxicity from topical, vaginal, or oral-gel use of Oromax is unlikely given minimal systemic absorption; however, accidental large oral ingestion (especially by children) may occur.

If accidental ingestion of a large amount of Oromax occurs, or if symptoms such as nausea, vomiting, or unusual drowsiness develop, seek immediate medical attention or contact a poison control center / emergency services. Do not attempt home treatment for suspected overdose; bring the product packaging when seeking care.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not freeze. Keep the container tightly closed.

Renal impairment

No dosage adjustment is generally required for topical, vaginal, or oral-gel Oromax given its minimal systemic absorption; specific renal-dosing studies are limited as this is a topically/locally acting agent.

Hepatic impairment

No specific dosage adjustment is established for topical, vaginal, or oral-gel Oromax; however, since Oromax inhibits hepatic CYP enzymes, caution is advised with extensive use in patients with significant hepatic impairment, and physician guidance should be sought.

Elderly

No specific dose adjustment is required for elderly patients using Oromax; use as directed, with the same precautions regarding drug interactions (particularly anticoagulants) that are common in this age group.

Pediatric

See Pediatric Use.

Duration of treatment with Oromax depends on the indication and formulation: typically 3–7 nights for vaginal formulations, 2–4 weeks for cutaneous fungal infections (continuing for at least one week after symptoms disappear), 2 weeks for tinea versicolor, and 1–2 weeks for oral thrush (continuing for at least one week after symptoms resolve). Do not stop treatment early even if symptoms improve, and consult a physician if there is no improvement within the expected timeframe or if symptoms recur.

Miconazole Nitrate is classified as an imidazole antifungal (azole antifungal), within the broader group of topical/local antifungal agents.

Miconazole Nitrate inhibits fungal 14-alpha-demethylase (a cytochrome P450-dependent enzyme), blocking conversion of lanosterol to ergosterol. This depletes ergosterol in the fungal cell membrane and allows accumulation of toxic methylated sterol precursors, disrupting membrane integrity and function, which is fungistatic at low concentrations and fungicidal at higher concentrations.

C

Use of Oromax in children should follow age-appropriate formulations and dosing:

• Oral gel (oropharyngeal candidiasis): may be used in infants and children; infants are typically given 1.25 mL four times daily and children 2 years and older 2.5 mL four times daily, applied after meals. In infants, apply small amounts carefully to the inside of the cheeks to reduce the risk of choking, and avoid placing gel at the back of the throat.
• Topical cream (skin infections, including candidal diaper dermatitis): may be used in children as directed by a physician, applied sparingly to the affected area.
• Safety and efficacy of vaginal formulations of Oromax have not been established in prepubertal children, and these formulations are not intended for pediatric vaginal use.
• Use in neonates and very young infants should be under direct medical supervision.